VAERS reports by lot

Moderna COVID-19 lot 046L21A: VAERS reports

309 VAERS reports list lot 046L21A as a Moderna COVID-19 vaccine, received between 2021-10-09 and 2024-03-14. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
309
Reports
10%
Marked serious
6
With a death outcome
21
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)17623%
Respiratory9813%
Neurological9412%
Cardiac / Cardiovascular8912%
Injection-site / Local reaction7710%
Gastrointestinal739%
Dermatological (non-injection-site)496%
Musculoskeletal405%
Allergic / Anaphylactic304%
Psychiatric / Neuropsychiatric162%
Thrombotic / Hematological152%
Autoimmune / Immune-mediated101%
Reproductive / Menstrual30%

Where reports came from

U.S. state of the reporter, where given (top 12).

California82
Washington17
New Jersey17
New York16
Arizona14
Ohio13
Texas11
Michigan10
Massachusetts9
Florida8
Virginia8
Illinois7

Reports by month received

2021-101
2022-0231
2022-0373
2022-0468
2022-0534
2022-063
2022-0730
2022-085
2022-096
2022-104
2022-112
2022-127
2023-011
2023-022
2023-034
2023-045
2023-055
2023-071
2023-083
2023-1023
2024-031

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.